Raul M Luque

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6025263/publications.pdf

Version: 2024-02-01

199 papers 6,450 citations

66250 44 h-index 67 g-index

208 all docs

208 docs citations

208 times ranked 6069 citing authors

#	Article	IF	CITATIONS
1	Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. Annals of the Rheumatic Diseases, 2022, 81, 56-67.	0.5	18
2	Epigenetic and postâ€transcriptional regulation of somatostatin receptor subtype 5 (SST ₅) in pituitary and pancreatic neuroendocrine tumors. Molecular Oncology, 2022, 16, 764-779.	2.1	6
3	Chronodisruption and diet associated with increased cardiometabolic risk in coronary heart disease patients: the CORDIOPREV study. Translational Research, 2022, 242, 79-92.	2.2	15
4	SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1Âsplicing and mTOR/ß-catenin pathways imbalances. Journal of Experimental and Clinical Cancer Research, 2022, 41, 39.	3.5	19
5	Diabetes Remission Is Modulated by Branched Chain Amino Acids According to the Diet Consumed: From the CORDIOPREV Study. Molecular Nutrition and Food Research, 2022, 66, e2100652.	1.5	2
6	Morphofunctional and Molecular Assessment of Nutritional Status in Head and Neck Cancer Patients Undergoing Systemic Treatment: Role of Inflammasome in Clinical Nutrition. Cancers, 2022, 14, 494.	1.7	9
7	Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. International Journal of Molecular Sciences, 2022, 23, 1143.	1.8	5
8	Long-term consumption of a mediterranean diet or a low-fat diet on kidney function in coronary heart disease patients: The CORDIOPREV randomized controlled trial. Clinical Nutrition, 2022, 41, 552-559.	2.3	23
9	Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Molecular Therapy - Nucleic Acids, 2022, 27, 1164-1178.	2.3	4
10	Integrative clinical, radiological and molecular analysis for predicting remission and recurrence of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	3
11	Sarcopenia and Ghrelin System in the Clinical Outcome and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2022, 14, 111.	1.7	7
12	MiRNAs profile as biomarkers of nutritional therapy for the prevention of type 2 diabetes mellitus: From the CORDIOPREV study. Clinical Nutrition, 2021, 40, 1028-1038.	2.3	21
13	Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Cancer Letters, 2021, 496, 72-83.	3.2	48
14	A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study. Molecular Therapy - Nucleic Acids, 2021, 23, 255-263.	2.3	9
15	Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e696-e710.	1.8	19
16	Influence of Obesity in the miRNome: miR-4454, a Key Regulator of Insulin Response Via Splicing Modulation in Prostate. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e469-e484.	1.8	20
17	The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. Peerl, 2021, 9, e10280.	0.9	5
18	Recommendations on the pathological report of pituitary tumors. A consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2021, 68, 196-207.	0.1	1

#	Article	IF	Citations
19	Recomendaciones sobre el diagnóstico e informe anatomopatológico de los tumores neuroendocrinos hipofisarios. Consenso de expertosÂde la Sociedad Española de Endocrinologia y Nutrición y de la Sociedad Española de AnatomÃa Patológica. Endocrinologia, Diabetes Y NutriciÓn, 2021, 68, 196-207.	0.1	2
20	Adipocyte-derived extracellular vesicles regulate survival and function of pancreatic \hat{l}^2 cells. JCI Insight, 2021, 6, .	2.3	55
21	A novel human tumoroid 3D model of sustained ACTH-secreting cell cultures to study critically needed therapies for Cushing's disease. EBioMedicine, 2021, 67, 103368.	2.7	0
22	Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers, 2021, 13, 3097.	1.7	8
23	Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial. Translational Research, 2021, 238, 12-24.	2.2	10
24	In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4956-e4968.	1.8	5
25	Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4917-e4934.	1.8	6
26	Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers, 2021, 13, 3950.	1.7	4
27	Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. Antioxidants, 2021, 10, 1348.	2.2	10
28	Growth hormone-releasing hormone-secreting pulmonary neuroendocrine tumor associated with pituitary hyperplasia and somatotropinoma. Archives of Endocrinology and Metabolism, 2021, 65, 648-663.	0.3	2
29	Impaired mRNA splicing and proteostasis in preadipocytes in obesity-related metabolic disease. ELife, 2021, 10, .	2.8	10
30	Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma. Cancers, 2021, 13, 4828.	1.7	4
31	Editorial: Pathophysiological Interrelationship Between Obesity, Metabolic Diseases, and Cancer. Frontiers in Oncology, 2021, 11, 755735.	1.3	3
32	Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. Current Opinion in Pharmacology, 2021, 60, 17-26.	1.7	11
33	Evolution of Metabolic Phenotypes of Obesity in Coronary Patients after 5 Years of Dietary Intervention: From the CORDIOPREV Study. Nutrients, 2021, 13, 4046.	1.7	3
34	Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Journal of Experimental and Clinical Cancer Research, 2021, 40, 382.	3 . 5	25
35	Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study. Clinical Nutrition, 2020, 39, 492-500.	2.3	13
36	Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial. European Journal of Nutrition, 2020, 59, 2099-2110.	1.8	45

#	Article	IF	CITATIONS
37	A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells. Neuroendocrinology, 2020, 110, 70-82.	1.2	20
38	A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors. Clinical Cancer Research, 2020, 26, 957-969.	3.2	34
39	Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBioMedicine, 2020, 51, 102547.	2.7	71
40	Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. Journal of Clinical Medicine, 2020, 9, 3052.	1.0	9
41	A supervised machine learning-based methodology for analyzing dysregulation in splicing machinery: An application in cancer diagnosis. Artificial Intelligence in Medicine, 2020, 108, 101950.	3.8	8
42	Dietary Intervention Modulates the Expression of Splicing Machinery in Cardiovascular Patients at High Risk of Type 2 Diabetes Development: From the CORDIOPREV Study. Nutrients, 2020, 12, 3528.	1.7	7
43	Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain, 2020, 143, 3273-3293.	3.7	54
44	Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer. Journal of Clinical Medicine, 2020, 9, 1703.	1.0	5
45	Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. Journal of Clinical Medicine, 2020, 9, 1838.	1.0	5
46	Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors. Neuroendocrinology, 2020, 110, 1028-1041.	1.2	12
47	Postprandial Lipemia Modulates Pancreatic Alpha-Cell Function in the Prediction of Type 2 Diabetes Development: The CORDIOPREV Study. Journal of Agricultural and Food Chemistry, 2020, 68, 1266-1275.	2.4	4
48	Age-dependent effect of metabolic phenotypes on carotid atherosclerotic disease in coronary heart disease patients (CORDIOPREV study). BMC Geriatrics, 2020, 20, 151.	1.1	7
49	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Translational Research, 2019, 212, 89-103.	2.2	47
50	Imaging and Manipulating Pituitary Function in the Awake Mouse. Endocrinology, 2019, 160, 2271-2281.	1.4	11
51	A Supervised Methodology for Analyzing Dysregulation in Splicing Machinery: An Application in Cancer Diagnosis. , 2019, , .		0
52	Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 1400.	1.0	16
53	Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. Cancers, 2019, 11, 1439.	1.7	30
54	Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3389-3402.	1.8	52

#	Article	IF	Citations
55	Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. European Journal of Clinical Investigation, 2019, 49, e13146.	1.7	14
56	CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. British Journal of Cancer, 2019, 120, 1120-1128.	2.9	25
57	Eâ€cadherin expression is associated with somatostatin analogue response in acromegaly. Journal of Cellular and Molecular Medicine, 2019, 23, 3088-3096.	1.6	32
58	Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Translational Research, 2019, 211, 147-160.	2.2	17
59	Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3501-3513.	1.8	30
60	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	2.6	51
61	Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Scientific Reports, 2019, 9, 1122.	1.6	21
62	Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 2056.	1.0	8
63	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs, 2019, 79, 21-42.	4.9	54
64	Clinical association of metabolic syndrome, Câ€reactive protein and testosterone levels with clinically significant prostate cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 934-942.	1.6	19
65	Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 57-73.	1.8	38
66	Cortistatin regulates glucose-induced electrical activity and insulin secretion in mouse pancreatic beta-cells. Molecular and Cellular Endocrinology, 2019, 479, 123-132.	1.6	5
67	Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 585-599.	1.6	16
68	Mouse models of endocrine tumors. Journal of Endocrinology, 2019, 240, R73-R96.	1.2	12
69	Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinologica, 2019, 44, 109-128.	1.7	23
70	Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Scientific Reports, 2018, 8, 6173.	1.6	19
71	Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin. Journal of Endocrinology, 2018, 237, 217-227.	1.2	11
72	Molecular evidence and clinical importance of $\hat{l}^2\hat{a}\in \mathbb{R}$ rrestins expression in patients with acromegaly. Journal of Cellular and Molecular Medicine, 2018, 22, 2110-2116.	1.6	18

#	Article	IF	CITATIONS
73	Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. Journal of Cellular and Molecular Medicine, 2018, 22, 1640-1649.	1.6	44
74	Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: Lessons from human and non-human primate models. Molecular and Cellular Endocrinology, 2018, 463, 4-22.	1.6	22
75	In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis, 2018, 39, 447-457.	1.3	19
76	Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine, 2018, 59, 426-437.	1.1	31
77	Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBioMedicine, 2018, 37, 356-365.	2.7	29
78	A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Experimental and Molecular Medicine, 2018, 50, 1-12.	3.2	80
79	Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 179-192.	2.6	32
80	Plasma ghrelin Oâ€acyltransferase (GOAT) enzyme levels: A novel nonâ€invasive diagnosis tool for patients with significant prostate cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5688-5697.	1.6	17
81	Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clinical and Translational Gastroenterology, 2018, 9, e196.	1.3	8
82	The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions. Cellular Physiology and Biochemistry, 2018, 49, 1444-1459.	1,1	11
83	THU0060â€Alterations of splicing in leukocytes from rheumatoid arthritis patients and its influence on the autoimmune, inflammatory and atherothrombotic profile of the disease. potential role of u4atac. , 2018, , .		0
84	Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. Growth Hormone and IGF Research, 2017, 33, 23-27.	0.5	15
85	Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and <scp>IGF</scp> 1. Journal of Cellular and Molecular Medicine, 2017, 21, 1893-1904.	1.6	17
86	BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Scientific Reports, 2017, 7, 42002.	1.6	27
87	The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer, 2017, 109, 128-136.	0.9	15
88	Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways. Molecular Cancer Research, 2017, 15, 862-874.	1.5	30
89	Adipokines (Leptin, Adiponectin, Resistin) Differentially Regulate All Hormonal Cell Types in Primary Anterior Pituitary Cell Cultures from Two Primate Species. Scientific Reports, 2017, 7, 43537.	1.6	41
90	FRIO429â€Dysregulation of the splicing machinery in leukocytes from ankylosing spondylitis patients is associated to disease pathogenesis. , 2017, , .		0

#	Article	IF	CITATIONS
91	Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. Prostate, 2017, 77, 1499-1511.	1.2	24
92	Adipokines and Their Receptors Are Widely Expressed and Distinctly Regulated by the Metabolic Environment in the Prostate of Male Mice: Direct Role Under Normal and Tumoral Conditions. Endocrinology, 2017, 158, 3540-3552.	1.4	11
93	The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB Journal, 2017, 31, 4682-4696.	0.2	41
94	AB0128â€Alterations of the splicing machinery components in leukocytes from patients with systemic lupus erythematosus influences its development and atherothrombotic profile and drives the therapeutic response., 2017,,.		0
95	Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. Oncotarget, 2017, 8, 81462-81474.	0.8	27
96	The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Molecular Cancer, 2017, 16, 146.	7.9	41
97	Obesity- and gender-dependent role of endogenous somatostatin and cortistatin in the regulation of endocrine and metabolic homeostasis in mice. Scientific Reports, 2016, 6, 37992.	1.6	12
98	El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la EndocrinologÃa espaÁ±ola por la medicina individualizada y la investigación traslacional. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 274-284.	0.8	18
99	Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. Journal of Endocrinology, 2016, 231, 135-145.	1.2	62
100	Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker. Cancer Letters, 2016, 383, 125-134.	3.2	30
101	The Molecular Registry of Pituitary Adenomas (REMAH): A bet by Spanish Endocrinology for the future of individualized medicine and translational research. EndocrinologÃa Y Nutrición (English Edition), 2016, 63, 274-284.	0.5	13
102	Role of the Kiss1/Kiss1r system in the regulation of pituitary cell function. Molecular and Cellular Endocrinology, 2016, 438, 100-106.	1.6	31
103	Cortistatin Is a Key Factor Regulating the Sex-Dependent Response of the GH and Stress Axes to Fasting in Mice. Endocrinology, 2016, 157, 2810-2823.	1.4	9
104	Models of GH deficiency in animal studies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 693-704.	2.2	6
105	Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Research, 2016, 18, 29.	2.2	5
106	Fasting modulates GH/IGF-I axis and its regulatory systems in the mammary gland of female mice: Influence of endogenous cortistatin. Molecular and Cellular Endocrinology, 2016, 434, 14-24.	1.6	3
107	Serum Galanin Levels in Young Healthy Lean and Obese Non-Diabetic Men during an Oral Glucose Tolerance Test. Scientific Reports, 2016, 6, 31661.	1.6	12
108	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Oncotarget, 2016, 7, 60110-60122.	0.8	16

#	Article	IF	CITATIONS
109	Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 6593-6608.	0.8	39
110	Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly. Scientific Reports, 2015, 5, 16298.	1.6	8
111	In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features. Scientific Reports, 2015, 5, 8714.	1.6	53
112	Metabolic and Gonadotropic Impact of Sequential Obesogenic Insults in the Female: Influence of the Loss of Ovarian Secretion. Endocrinology, 2015, 156, 2984-2998.	1.4	27
113	Melatonin Regulates Somatotrope and Lactotrope Function Through Common and Distinct Signaling Pathways in Cultured Primary Pituitary Cells From Female Primates. Endocrinology, 2015, 156, 1100-1110.	1.4	16
114	Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation,) Tj ETQq0 0 0 rgBT	/9verlock	10 Tf 50 54
115	The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine, 2015, 50, 442-452.	1.1	17
116	Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache. Growth Hormone and IGF Research, 2015, 25, 262-267.	0.5	23
117	Obesity Alters Gene Expression for GH/IGF-I Axis in Mouse Mammary Fat Pads: Differential Role of Cortistatin and Somatostatin. PLoS ONE, 2015, 10, e0120955.	1.1	7
118	In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters. Oncotarget, 2015, 6, 19619-19633.	0.8	31
119	Long- But Not Short-Term Adult-Onset, Isolated GH Deficiency in Male Mice Leads to Deterioration of \hat{l}^2 -Cell Function, Which Cannot Be Accounted for by Changes in \hat{l}^2 -Cell Mass. Endocrinology, 2014, 155, 726-735.	1.4	24
120	Dietary fat alters the expression of cortistatin and ghrelin systems in the PBMCs of elderly subjects: Putative implications in the postprandial inflammatory response. Molecular Nutrition and Food Research, 2014, 58, 1897-1906.	1.5	15
121	Obestatin Plays an Opposite Role in the Regulation of Pituitary Somatotrope and Corticotrope Function in Female Primates and Male/Female Mice. Endocrinology, 2014, 155, 1407-1417.	1.4	15
122	Somatotropinomas, But Not Nonfunctioning Pituitary Adenomas, Maintain a Functional Apoptotic RET/Pit1/ARF/p53 Pathway That Is Blocked by Excess GDNF. Endocrinology, 2014, 155, 4329-4340.	1.4	14
123	Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, 69-76.	0.8	11
124	Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease. EndocrinologÃa Y Nutrición (English Edition), 2014, 61, 69-76.	0.5	5
125	Both Estrogen Receptor \hat{l}_{\pm} and \hat{l}^{2} Stimulate Pituitary GH Gene Expression. Molecular Endocrinology, 2014, 28, 40-52.	3.7	58
126	Porcine sst1 can physically interact with other somatostatin receptors, and its expression is regulated by metabolic/inflammatory sensors. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E483-E493.	1.8	1

#	Article	IF	Citations
127	Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice. Carcinogenesis, 2014, 35, 2467-2473.	1.3	12
128	Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight. Journal of Endocrinology, 2014, 220, R1-R24.	1.2	7 5
129	Obesity-Induced Hypogonadism in the Male: Premature Reproductive Neuroendocrine Senescence and Contribution of Kiss1-Mediated Mechanisms. Endocrinology, 2014, 155, 1067-1079.	1.4	56
130	Variability in Quantitative Expression of Receptors in Nonfunctioning Pituitary Macroadenomas an Opportunity for Targeted Medical Therapy. Endocrine Practice, 2014, 20, 15-25.	1.1	6
131	The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer. PLoS ONE, 2014, 9, e85527.	1.1	29
132	Nutritional, hormonal, and depot-dependent regulation of the expression of the small GTPase Rab18 in rodent adipose tissue. Journal of Molecular Endocrinology, 2013, 50, 19-29.	1.1	11
133	A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4160-4169.	1.8	56
134	The Rise in Growth Hormone during Starvation Does Not Serve to Maintain Glucose Levels or Lean Mass but Is Required for Appropriate Adipose Tissue Response in Female Mice. Endocrinology, 2013, 154, 263-269.	1.4	32
135	Endogenous Somatostatin Is Critical in Regulating the Acute Effects of l-Arginine on Growth Hormone and Insulin Release in Mice. Endocrinology, 2013, 154, 2393-2398.	1.4	7
136	Paradoxical Effect of Cortistatin Treatment and Its Deficiency on Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2013, 191, 2144-2154.	0.4	32
137	Insulin and IGF-I Inhibit GH Synthesis and Release in Vitro and in Vivo by Separate Mechanisms. Endocrinology, 2013, 154, 2410-2420.	1.4	45
138	Role of Endogenous Cortistatin in the Regulation of Ghrelin System Expression at Pancreatic Level under Normal and Obese Conditions. PLoS ONE, 2013, 8, e57834.	1.1	8
139	Peripubertal-onset but not adult-onset obesity increases IGF-I and drives development of lean mass, which may lessen the metabolic impairment in adult obesity. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E1151-E1157.	1.8	18
140	Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E1325-E1334.	1.8	16
141	Homologous and Heterologous in Vitro Regulation of Pituitary Receptors for Somatostatin, Growth Hormone (GH)-Releasing Hormone, and Ghrelin in a Nonhuman Primate (Papio anubis). Endocrinology, 2012, 153, 264-272.	1.4	17
142	Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Human Reproduction, 2012, 27, 2117-2129.	0.4	33
143	The Adult Pituitary Shows Stem/Progenitor Cell Activation in Response to Injury and Is Capable of Regeneration. Endocrinology, 2012, 153, 3224-3235.	1.4	87
144	Obestatin regulates adipocyte function and protects against dietâ€induced insulin resistance and inflammation. FASEB Journal, 2012, 26, 3393-3411.	0.2	79

#	Article	IF	Citations
145	The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells. PLoS ONE, 2012, 7, e48411.	1.1	34
146	Regulation of lipin 1 by nutritional status, adiponectin, sex and pituitary function in rat white adipose tissue. Physiology and Behavior, 2012, 105, 777-783.	1.0	13
147	Measurement of Free Cytosolic Calcium Concentration ([Ca2+]i) in Single CHO-K1 Cells. Bio-protocol, 2012, 2, .	0.2	0
148	Role of ghrelin system in neuroprotection and cognitive functions: Implications in Alzheimer's disease. Peptides, 2011, 32, 2225-2228.	1.2	91
149	A Novel Human Ghrelin Variant (In1-Ghrelin) and Ghrelin-O-Acyltransferase Are Overexpressed in Breast Cancer: Potential Pathophysiological Relevance. PLoS ONE, 2011, 6, e23302.	1.1	67
150	Truncated somatostatin receptors as new players in somatostatin–cortistatin pathophysiology. Annals of the New York Academy of Sciences, 2011, 1220, 6-15.	1.8	45
151	Does the pituitary somatotrope play a primary role in regulating GH output in metabolic extremes?. Annals of the New York Academy of Sciences, 2011, 1220, 82-92.	1.8	23
152	Elevated GH/IGF-I, Due to Somatotrope-Specific Loss of Both IGF-I and Insulin Receptors, Alters Glucose Homeostasis and Insulin Sensitivity in a Diet-Dependent Manner. Endocrinology, 2011, 152, 4825-4837.	1.4	32
153	Cortistatin Is Not a Somatostatin Analogue but Stimulates Prolactin Release and Inhibits GH and ACTH in a Gender-Dependent Fashion: Potential Role of Ghrelin. Endocrinology, 2011, 152, 4800-4812.	1.4	59
154	The Somatotrope as a Metabolic Sensor: Deletion of Leptin Receptors Causes Obesity. Endocrinology, 2011, 152, 69-81.	1.4	45
155	Impact of <i>gsp</i> Oncogene on the mRNA Content for Somatostatin and Dopamine Receptors in Human Somatotropinomas. Neuroendocrinology, 2011, 93, 40-47.	1.2	19
156	Kisspeptin Regulates Gonadotroph and Somatotroph Function in Nonhuman Primate Pituitary via Common and Distinct Signaling Mechanisms. Endocrinology, 2011, 152, 957-966.	1.4	85
157	Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10. European Journal of Endocrinology, 2011, 164, 355-362.	1.9	27
158	Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E46-E54.	1.8	34
159	Metabolic Impact of Adult-Onset, Isolated, Growth Hormone Deficiency (AOiGHD) Due to Destruction of Pituitary Somatotropes. PLoS ONE, 2011, 6, e15767.	1.1	60
160	Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cellular and Molecular Life Sciences, 2010, 67, 1147-1163.	2.4	59
161	Expression of Somatostatin, Cortistatin, and Their Receptors, as well as Dopamine Receptors, but not of Neprilysin, are Reduced in the Temporal Lobe of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2010, 20, 465-475.	1.2	67
162	The Somatotrope as a Metabolic Sensor: Deletion of Leptin Receptors Causes Obesity. Endocrine Reviews, 2010, 31, 941-941.	8.9	1

#	Article	IF	CITATIONS
163	Somatostatin and its receptors from fish to mammals. Annals of the New York Academy of Sciences, 2010, 1200, 43-52.	1.8	66
164	A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2497-2502.	1.8	88
165	Targeted Deletion of Somatotroph Insulin-Like Growth Factor-I Signaling in a Cell-Specific Knockout Mouse Model. Molecular Endocrinology, 2010, 24, 1077-1089.	3.7	47
166	Avances en biologÃa molecular en patologÃa neuroendocrina. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2010, 57, 2-6.	0.8	1
167	Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. Molecular and Cellular Endocrinology, 2010, 317, 154-160.	1.6	101
168	Expression of the Ghrelin and Neurotensin Systems is Altered in the Temporal Lobe of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2010, 22, 819-828.	1.2	89
169	Use of the Metallothionein Promoter-Human Growth Hormone-Releasing Hormone (GHRH) Mouse to Identify Regulatory Pathways that Suppress Pituitary Somatotrope Hyperplasia and Adenoma Formation due to GHRH-Receptor Hyperactivation. Endocrinology, 2009, 150, 3177-3185.	1.4	16
170	Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1931-1937.	1.8	120
171	Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2634-2643.	1.8	125
172	Understanding the Multifactorial Control of Growth Hormone Release by Somatotropes. Annals of the New York Academy of Sciences, 2009, 1163, 137-153.	1.8	88
173	KiSS-1/kisspeptins and the metabolic control of reproduction: Physiologic roles and putative physiopathological implications. Peptides, 2009, 30, 139-145.	1.2	149
174	Role of endogenous somatostatin in regulating GH output under basal conditions and in response to metabolic extremes. Molecular and Cellular Endocrinology, 2008, 286, 155-168.	1.6	42
175	Are somatostatin and cortistatin two siblings in regulating endocrine secretions? In vitro work ahead. Molecular and Cellular Endocrinology, 2008, 286, 128-134.	1.6	57
176	Quantitative analysis of somatostatin receptor subtypes ($1\hat{a}\in$ 5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology, 2008, 158, 295-303.	1.9	160
177	Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat. Endocrinology, 2008, 149, 1366-1376.	1.4	31
178	Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology, 2007, 156, 65-74.	1.9	196
179	Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E891-E899.	1.8	72
180	Nutritional regulation of adipose tissue apolipoprotein E expression. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E203-E209.	1.8	42

#	Article	IF	CITATIONS
181	Reporter Expression, Induced by a Growth Hormone Promoter-Driven Cre Recombinase (rGHp-Cre) Transgene, Questions the Developmental Relationship between Somatotropes and Lactotropes in the Adult Mouse Pituitary Gland. Endocrinology, 2007, 148, 1946-1953.	1.4	63
182	Evidence that Ghrelin Is as Potent as Growth Hormone (GH)-Releasing Hormone (GHRH) in Releasing GH from Primary Pituitary Cell Cultures of a Nonhuman Primate (Papio anubis), Acting through Intracellular Signaling Pathways Distinct from GHRH. Endocrinology, 2007, 148, 4440-4449.	1.4	60
183	Severity of the Catabolic Condition Differentially Modulates Hypothalamic Expression of Growth Hormone-Releasing Hormone in the Fasted Mouse: Potential Role of Neuropeptide Y and Corticotropin-Releasing Hormone. Endocrinology, 2007, 148, 300-309.	1.4	74
184	Regulation of Hypothalamic Expression of KiSS-1 and GPR54 Genes by Metabolic Factors: Analyses Using Mouse Models and a Cell Line. Endocrinology, 2007, 148, 4601-4611.	1.4	235
185	Identification of a mouse ghrelin gene transcript that contains intron 2 and is regulated in the pituitary and hypothalamus in response to metabolic stress. Journal of Molecular Endocrinology, 2007, 38, 511-521.	1.1	50
186	Gender-Dependent Role of Endogenous Somatostatin in Regulating Growth Hormone-Axis Function in Mice. Endocrinology, 2007, 148, 5998-6006.	1.4	40
187	A mutant allele of BARA/LIN-9 rescues the cdk4â^'/â^' phenotype by releasing the repression on E2F-regulated genes. Experimental Cell Research, 2006, 312, 2465-2475.	1.2	12
188	Impact of Obesity on the Growth Hormone Axis: Evidence for a Direct Inhibitory Effect of Hyperinsulinemia on Pituitary Function. Endocrinology, 2006, 147, 2754-2763.	1.4	135
189	Identification of the Somatostatin Receptor Subtypes (sst) Mediating the Divergent, Stimulatory/Inhibitory Actions of Somatostatin on Growth Hormone Secretion. Endocrinology, 2006, 147, 2902-2908.	1.4	30
190	Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. Journal of Molecular Endocrinology, 2006, 37, 25-38.	1.1	60
191	Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E395-E403.	1.8	69
192	Mutation of BARA/LINâ€9 rescues the CDK4â€null phenotype by releasing the repression on E2Fâ€regulated genes. FASEB Journal, 2006, 20, A38.	0.2	0
193	Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA. Journal of Molecular Endocrinology, 2004, 32, 437-448.	1.1	21
194	Homologous and Heterologous Regulation of Pituitary Receptors for Ghrelin and Growth Hormone-Releasing Hormone. Endocrinology, 2004, 145, 3182-3189.	1.4	53
195	Role of Ca2+ in the secretory and biosynthetic response of porcine gonadotropes to substance P and gonadotropin-releasing hormone. Regulatory Peptides, 2003, 116, 43-52.	1.9	6
196	Intracellular Signaling Mechanisms Mediating Ghrelin-Stimulated Growth Hormone Release in Somatotropes. Endocrinology, 2003, 144, 5372-5380.	1.4	132
197	Secretory Plasticity of Pituitary Cells: A Mechanism of Hormonal Regulation. Archives of Physiology and Biochemistry, 2002, 110, 106-112.	1.0	8
198	Research progress in the stimulatory inputs regulating growth hormone (GH) secretion. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2002, 132, 141-150.	0.7	16

#	Article	IF	CITATIONS
199	A Gene Variation at the ZPR1 Locus (rs964184) Interacts With the Type of Diet to Modulate Postprandial Triglycerides in Patients With Coronary Artery Disease: From the Coronary Diet Intervention With Olive Oil and Cardiovascular Prevention Study. Frontiers in Nutrition, 0, 9, .	1.6	3